Neuroscience learning from longitudinal cohort studies of Alzheimer's disease: Lessons for disease-modifying drug programs and an introduction to the Center for Neurodegeneration and Translational Neuroscience.
Neuroscience learning from longitudinal cohort studies of Alzheimer's disease: Lessons for disease-modifying drug programs and an introduction to the Center for Neurodegeneration and Translational Neuroscience.
复制标题
DOI：
10.1016/j.trci.2018.06.006
复制
发表时间：
2018
期刊：
影响因子：
--
通讯作者：
Ritter A
中科院分区：
文献类型：
--
作者：
Miller JB;Cummings J;Nance C;Ritter A
开发阿尔茨海默病的疾病修正疗法是一项紧迫的公共卫生紧急事件。最近的失败突显了药物开发项目面临的重大挑战。纵向队列研究是促进对这种多因素、进展缓慢的疾病的了解的理想选择。在特别版的这一部分，我们回顾了纵向队列研究中的几个重要教训，这些研究在疾病修正疗法的开发中应该被考虑。在最后一节中，我们介绍了神经变性和转化性神经科学中心的临床队列。这项新建立的纵向研究旨在为早期阿尔茨海默病和帕金森病(PD)认知功能下降的神经成像和生物标记物(生物标记物)提供新的见解。
The development of disease-modifying therapies for Alzheimer's disease is an urgent public health emergency. Recent failures have highlighted the significant challenges faced by drug-development programs. Longitudinal cohort studies are ideal for promoting understanding of this multifactorial, slowly progressive disease. In this section of the special edition, we review several important lessons from longitudinal cohort studies which should be considered in disease-modifying therapy development. In the final section, we introduce the clinical cohort of the Center for Neurodegeneration and Translational Neuroscience. This newly established longitudinal study aims to provide new insights into the neuroimaging and biological marker (biomarkers) correlates of cognitive decline in early Alzheimer's disease and Parkinson's disease (PD).